Cilostazol.
Cilostazol is a phosphodiesterase III inhibitor that has been shown to be effective for treatment of symptomatic intermittent claudication. It is generally well tolerated, but is contraindicated in patients with severe heart failure because of the potential detrimental effects demonstrated by other agents in the same class. Additional studies are required to examine the long-term benefits of cilostazol therapy.
Cheng
J W
JW
Arnold & Marie Schwartz College of Pharmacy and Health Sciences, Long Island University, New York, New York, USA.
D000077407:Cilostazol; D000075202:Contraindications; D006801:Humans; D007383:Intermittent Claudication / Q000188:drug therapy*; D010726:Phosphodiesterase Inhibitors / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D013777:Tetrazoles / Q000627:therapeutic use*; D014665:Vasodilator Agents / Q000627:therapeutic use*
D010726:Phosphodiesterase Inhibitors; D013777:Tetrazoles; D014665:Vasodilator Agents; D000077407:Cilostazol